Expansion Into Venous Intervention And Cell Therapy Markets Will Shape Future Success

Key Takeaways

• Terumo's innovation and new market creation focus, including entering the venous intervention market, aim to drive future sales and revenue growth.
  
• Strategic cost control measures and operational efficiencies, along with manufacturing transfers, are enhancing profit margins and improving future net margins.
  
• Unpredictable macroeconomic conditions, restructuring expenses, and regional market risks could impact Terumo's margins and revenue amidst innovation and market entry challenges.

Catalysts

Engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.

• Terumo is actively investing in innovation with a focus on developing new products and solutions, such as entering the venous intervention market, which could drive significant future sales growth. This focus on R&D and new market creation is likely to impact future revenue growth positively.
  
• The company's cost control measures and operational efficiencies, including transferring manufacturing sites to Vietnam and Costa Rica, are expected to enhance profit margins. This ongoing focus on cost management is likely to improve future net margins.
  
• Terumo's upward revision of its full-year financial forecast, driven by strong first-half performance and favorable foreign exchange rates, indicates potential growth in earnings. This suggests that earnings could see a positive impact if current growth trends continue.
  
• Expansion in Therapeutic Apheresis and Blood Center businesses, driven by demand for cell and gene therapies, particularly in the U.S. and Europe, is expected to contribute to future revenue growth, indicating strong potential for increasing future revenues in these segments.
  
• The establishment of Terumo Ventures to promote venture investments signals a strategic push towards acquiring innovative technology and building an M&A pipeline, which can drive long-term revenue and earnings growth through strategic acquisitions and partnerships.

Terumo Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Terumo's revenue will grow by 7.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from 12.1% today to 14.8% in 3 years time.
• Analysts expect earnings to reach ¥181.3 billion (and earnings per share of ¥122.96) by about December 2027, up from ¥119.5 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting ¥203.0 billion in earnings, and the most bearish expecting ¥160.0 billion.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 31.8x on those 2027 earnings, down from 37.5x today. This future PE is lower than the current PE for the JP Medical Equipment industry at 36.0x.
• Analysts expect the number of shares outstanding to decline by 0.13% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.03%, as per the Simply Wall St company report.

Terumo Future Earnings Per Share Growth

Risks

• The unpredictable macroeconomic conditions, such as increased raw material prices and transportation costs, could impact Terumo's revenue and profit margins adversely in the future.
  
• The impact of centralized purchasing in China led to a decline in TIS sales, indicating potential risks to revenues in specific regional markets.
  
• The ongoing restructuring expenses in the Cardiovascular company suggest future financial uncertainty, which could affect net margins and earnings.
  
• The emphasis on innovation and entering new markets like venous interventions involves execution risk and competition, posing a challenge to achieving expected revenue growth.
  
• The fluctuation in foreign exchange rates, although favorable currently, presents a risk that could affect revenue and net income if rates shift unfavorably.

Valuation

• The analysts have a consensus price target of ¥3375.0 for Terumo based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ¥3810.0, and the most bearish reporting a price target of just ¥2800.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2027, revenues will be ¥1225.2 billion, earnings will come to ¥181.3 billion, and it would be trading on a PE ratio of 31.8x, assuming you use a discount rate of 5.0%.
• Given the current share price of ¥3025.0, the analyst's price target of ¥3375.0 is 10.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.